Independent Data Monitoring Committee (IDMC) finds clear efficacy for REGEN-COV™ (casirivimab with imdevimab) in Phase 3 COVID-19 outpatient outcomes trial

The analysis of interim data concluded that both doses reduced the rate of hospitalisation and death when compared to placebo, and the IDMC has recommended stopping enrolment into the placebo arm of the trial. The company will share detailed results when available.

Source:

Biospace Inc.